Dostarlimab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 241 publications

Immunotherapy-Induced Glutamic Acid Decarboxylase 65 Cerebellitis.

Immunotherapy-Induced Glutamic Acid Decarboxylase 65 Cerebellitis.

Journal: Cureus

Published: May 20, 2026

Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France.

Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: May 05, 2026

Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.

Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.

Journal: Science translational medicine

Published: April 22, 2026

Thrombus or Vegetation: A Diagnostic Dilemma in Cardiac Imaging.

Thrombus or Vegetation: A Diagnostic Dilemma in Cardiac Imaging.

Journal: Cureus

Published: April 18, 2026

Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.

Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.

Journal: Rheumatology international

Published: April 15, 2026

A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.

A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.

Journal: Gynecologic oncology

Published: April 13, 2026

Immunotherapy related organizing pneumonia mimicking metastatic progression in a patient with endometrial cancer: A case report.

Immunotherapy related organizing pneumonia mimicking metastatic progression in a patient with endometrial cancer: A case report.

Journal: Gynecologic oncology reports

Published: April 07, 2026

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Journal: Gynecologic oncology

Published: March 24, 2026

Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer.

Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer.

Journal: Cancer letters

Published: February 26, 2026

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France.

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: February 06, 2026

JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.

JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.

Journal: Future oncology (London, England)

Published: January 30, 2026

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.

Journal: JAMA network open

Published: January 28, 2026

Showing 1-12 of 241

Last Updated: 06/30/2026